3-Aethylcinnolin | 33852-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-Aethylcinnolin
• 英文别名: 3-ethyl-cinnoline；3-Ethylcinnoline
• CAS: 33852-50-5
• 化学式: C₁₀H₁₀N₂
• 分子量: 158.203
• InChiKey: SALXFJXLWRHBMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 2-Propene-1-Ones As Hsp 70 Inducers
  申请人：Kumar Prabhat

  公开号：US20080207608A1

  公开（公告）日：2008-08-28

  The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R 5 , R 6 , Q and Y are as defined in the specification. The present invention also relates to a process for preparing such compounds, compositions containing such compounds, and use of such compound and composition in medicine. The compounds of the general formula (I) induce HSP-70 and are useful for the treatment of diseases accompanying pathological stress in a living mammalian organism, including a human being, such as stroke, myocardial infarction, inflammatory disorder, hepatotoxicity, sepsis, diseases of viral origin, allograft rejection, tumourous diseases, gastric mucosal damage, brain haemorrhage, endothelial dysfunctions, diabetic complications, neuro-degenerative diseases, post-traumatic neuronal damage, acute renal failure, glaucoma and aging related skin degeneration.

  本发明涉及2-丙烯酮系列的新化合物，通式为（I），它们的衍生物，类似物，互变异构体，立体异构体，多晶形，药学上可接受的盐，药学上可接受的溶剂和含有它们的药学上可接受的组合物，其中R5，R6，Q和Y如规范中所定义。本发明还涉及制备这种化合物的过程，含有这种化合物的组合物，以及在医学上使用这种化合物和组合物。通式（I）的化合物诱导HSP-70，并用于治疗伴随病理应激的疾病，包括中风，心肌梗死，炎症性疾病，肝毒性，败血症，病毒性疾病，异体移植排斥，肿瘤性疾病，胃黏膜损伤，脑出血，内皮功能障碍，糖尿病并发症，神经退行性疾病，创伤后神经损伤，急性肾衰竭，青光眼和与衰老相关的皮肤退化。
• Pyridazine-modified ziegler-natta catalyst system
  申请人：Nagy Sandor

  公开号：US20110082270A1

  公开（公告）日：2011-04-07

  A modified Ziegler-Natta catalyst system, a method for preparing the catalyst system, and a process for polymerizing an olefin in the presence of the catalyst system are disclosed. The catalyst system comprises a titanium or vanadium compound, an aluminum compound, and a pyridazine. Improved properties such as increased molecular weight and narrowed molecular weight distribution are obtained.
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20220332713A1

  公开（公告）日：2022-10-20

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.
• [EN] SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4<br/>[FR] DÉRIVÉS DE QUINAZOLINONE SUBSTITUÉS ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DE MGLUR4
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2020021064A1

  公开（公告）日：2020-01-30

  The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.